CNTX•Context Therapeutics’ third-quarter 2026 net loss narrowed 21% year over year to $7.62 million. Cash totaled $34.41 million at September 30, 2026, with operations expected to be funded through early Q4 2027.
Research and development expenses fell 34% year over year to $5.72 million. The company said its $34.41 million in cash and cash equivalents at September 30, 2026, is expected to fund operations through early Q4 2027.
In evaluable patients with platinum-resistant ovarian cancer, weekly CTIM-76 dosing achieved a 22% confirmed response rate and median progression-free survival of 5.6 months. Phase 1b dose expansion is expected in Q1 2027, with initial efficacy data from every-three-week dosing due in Q2 2027.
